Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO-Academy-Meeting-2022-1000x250

The ESMO Academy 2022 programme is online

Access the online programme

Educational Co-Chairs

  • Viviane Hess, Basel, Switzerland
  • Karin Jordan, Heidelberg, Germany

Main themes

Year after year, the ESMO Academy has offered delegates a comprehensive, thorough update on the key topics in medical oncology, including methodology and interpretation of clinical trials, standard of care and future perspectives in the main tumour types, pharmacokinetics and drug interactions.

  • Colorectal Cancer
  • Prostate Cancer
  • Lung Cancer
  • Breast Cancer
  • Pharmacokinetics & Drug Interactions
  • Methodology and interpretation of clinical trials

Learning objectives

  • To understand the examination process and questions format.
  • To learn/update participants about the current standard of care for the main malignancies and the supporting clinical trials.
  • To learn about supportive care strategies: prophylaxis and therapy of tumour therapy induced side effects and tumor symptoms.
  • To learn about the pharmacokinetics of systemic therapies for the management of cancer and the interactions of these drugs.
  • To identify gaps in an individual’s knowledge for review and improvement.
  • To learn from the integrated assessments and question reviews with individual speakers and the speaker panel.

Accreditation

ESMO-MORA: The ESMO Academy 2022 will be submitted for ESMO-MORA category 1 points accreditation. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.

Disclaimer

All Speakers and Discussants are required to declare their interests, if any, and include a Declaration of Interest (DOI) slide at the start of their presentation(s).

The experts invited by ESMO as Discussants are selected on an individual basis to provide their own interpretation of the data and are not acting as ESMO spokespersons.

The ESMO recommendations on the clinical utility of new drugs are only presented in the ESMO Clinical Practice Guidelines and such recommendations represent the only official position of ESMO.

Webcast

The meeting webcasts will be available for all delegates and will include all the sessions of the official programme where speaker permission is granted. Once the meeting has finished, the webcasts will be available on OncologyPRO and will be accessible to all registered delegates and all ESMO Members, non-Member delegates for 24 months.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.